Active — Not RecruitingPhase 2

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

United States82 participantsStarted 2017-06-01

Plain-language summary

This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕Active or prior documented autoimmune or inflammatory disorders including but not limited to the following:
✕-GI Disorders: (including inflammatory bowel disease \[eg, ulcerative colitis, Crohn's disease\], diverticulitis (with the exception of a prior episode that has resolved), celiac disease, or other serious gastrointestinal chronic conditions associated with diarrhea.

What they're measuring

Progression Free Survival

Timeframe: 2 years

Trial details

NCT IDNCT03059485

SponsorBeth Israel Deaconess Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-04

View on ClinicalTrials.gov More Acute Myelogenous Leukemia trials